Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Nedaplatin for Injection accepted by the National Medical Products Administration. This drug is intended for treating various cancers, including head and neck cancer, lung cancer, and ovarian carcinoma. The acceptance marks a significant step in the company’s drug development efforts, potentially enhancing its market position in the oncology sector.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products, with a market focus on innovative drug development and healthcare services.
Average Trading Volume: 9,168,955
Technical Sentiment Signal: Buy
Current Market Cap: HK$72.71B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.